We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Biomarker Panel Evaluated for Primary Hyperoxaluria Patients

By LabMedica International staff writers
Posted on 27 Apr 2020
Primary hyperoxaluria (PH) is a group of autosomal recessive disorders characterized by recurrent urinary stones and nephrocalcinosis. More...
Roughly half of PH patients present with advanced chronic kidney disease (CKD) at the time of diagnosis.

Three forms of PH have been recognized based on the underlying genetic defects. Mutations in the AGXT, GRHPR, and HOGA1 genes cause primary hyperoxaluria types 1, 2, and 3, respectively. The main biochemical defect in PH is overproduction of oxalate due to enzyme deficiencies, primarily in the liver. The excess oxalate must then be excreted by the kidney. In the kidney oxalate can combine with calcium within renal tubules leading to nephrocalcinosis and kidney stones.

Nephrologists and their colleagues from the Mayo Clinic (Rochester, MN, USA) enrolled 30 PH patients who had one or more biobanked urine specimens and no prior history of end stage renal disease (ESRD) or organ transplantation. A cohort of 47 non-stone forming adults in good general health without kidney disease or diabetes (22 women, 25 men, ages ranging from 23 to 77 years) who completed 24-hour urine collections on a free choice diet served as the adult control group to establish an adult reference range for the urine biomarkers.

The scientists used a panel of biomarkers that reflect different nephron sites and potential mechanisms of injury (clusterin, neutrophil gelatinase-associated lipocalin (NGAL), 8-isoprostane (8IP), monocyte-chemoattractant protein 1 (MCP-1), liver-type fatty acid binding protein (L-FABP), heart-type fatty acid binding protein (H-FABP), and osteopontin (OPN) were measured in 114 urine specimens from 30 PH patients over multiple visits. Generalized estimating equations were used to assess associations between biomarkers and 24 hour urine excretions, calculated proximal tubular oxalate concentration (PTOx), and estimated glomerular filtration rate (eGFR).

The team reported that mean (±SD) age at first visit was 19.5 ± 16.6 years with an estimated glomerular filtration rate (eGFR) of 68.4 ± 21.0 mL/min/1.73m2. After adjustment for age, sex, and eGFR, a higher urine MCP-1 concentration as measured by Quantikine Human chemokine (C-C motif) ligand 2/ monocyte chemoattractant protein-1 (CCL2/MCP1) kit (R&D Systems, Minneapolis, MN, USA) and MCP-1/creatinine ratio was positively associated with calcium oxalate supersaturation (CaOx SS). Higher urine NGAL and NGAL/creatinine as well as OPN and OPN/creatinine were associated with higher eGFR. 8IP was negatively associated with PTOx and urinary Ox, but positively associated with CaOx SS.

The authors concluded that although the mechanisms are not entirely clear, CaOx crystallization in renal tubules has been considered as one of the critical therapeutic targets in the development of new therapeutic approach to treat PH. The association between urine level of MCP-1 and CaOx crystallization may suggest urine MCP-1 could be used as a marker to assist the evaluation for the effectiveness of treatments in PH patients. In addition, this association may suggest that MCP-1 signaling pathway might be in involved in the etiology of renal damage in PH. The study was published on April 15, 2020 in the journal BMC Nephrology.

Related Links:
Mayo Clinic
R&D Systems



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Automatic CLIA Analyzer
Shine i6000
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The SimpleScreen CRC platform uses multiomics, AI, and machine learning to analyze blood-based signals and detect cancer-associated patterns (Photo courtesy of Freenome)

Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions

Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.